Interactions between products of the mouse W locus, which encodes the c-kit tyrosine kinase receptor, and the SI locus, which encodes a ligand for c-kit receptor, which we have designated stem cell factor (SCF), have a critical role in the development of mast cells. Mice homozygous for mutations at either locus exhibit several phenotypic abnormalities including a virtual absence of mast cells. Moreover, the c-kit ligand SCF can induce the proliferation and maturation of normal mast cells in vitro or in vivo, and also can result in repair of the mast cell deficiency of S1/SI a mice in vivo. We now report that administration of SCF intradermally in vivo results in dermal mast cell activation and a mast cell-dependent acute inflammatory response. This effect is c-kit receptor dependent, in that it is not observed when SCF is administered to mice containing dermal mast cells expressing functionally inactive c-kit receptors, is observed with both glycosylated and nonglycosylated forms of SCF, and occurs at doses of SCF at least 10-fold lower on a molar basis than the minimally effective dose of the classical dermal mast cell-activating agent substance P. These findings represent the first demonstration in vivo that a c-kit ligand can result in the functional activation of any cellular lineage expressing the c-kit receptor, and suggest that interactions between the c-kit receptor and its ligand may influence mast cell biology through complex effects on proliferation, maturation, and function.
S
everal lines of evidence indicate that interactions between the c-kit tyrosine kinase receptor and its ligand critically regulate mouse mast cell development (reviewed in references 1-3). Mice with a double dose of mutant genes at either the W/c-kit locus on chromosome 5 or the Sl locus on chromosome 10, which encodes a ligand for the c-kit receptor that has been named stem cell factor (SCF) 1 (4-6), mast cell growth factor (7) (8) (9) , kit ligand (10) , and Steel factor (11) , are virtually devoid of mature mast cells (reviewed in references 1 and 12). Recombinant forms of the c-kit ligand induce proliferation of in vitro-derived immature IL,3-dependent mast cells (4, 5, 7, 9) or mature mast cells purified from 1 Abbreviations used in thispaper: BMCMC, IL-3-dependent, bone marrowderived cultured mast cells; CHO, Chinese hamster ovary cell; CTMC, connective tissue type mast cell(s); DNP30-40 HSA, DNP human serum albumin; 12SI-GPF, ~I-guinea pig fibrinogen; rrSCF 164, recombinant rat stem cell factor~4; SCF, stem cell factor. the peritoneal cavity of mice (3) . Recombinant rat SCF 164 (rrSCF164), representing the soluble form of the c-kit ligand, secreted by a Buffalo rat liver cell line (4) (5) (6) , not only induces proliferation of immature or mature mouse mast cells in vitro (3, 4) , but also promotes the maturation of IL-3-dependent, bone marrow-derived cultured mouse mast cells (BMCMC) in vitro (3) and induces the proliferation and maturation of mouse or rat mast cells when administered in vivo (2) . Administration of rrSCF 164 in vivo also can repair the macroc/tic anemia and the mast cell deficiency expressed by Sl/Sl a mice (2, 6) .
The effects of rrSCF 164 on mouse or rat mast cell proliferation and maturation, when taken together with the profound mast cell defidendes expressed by W or SI mutant mice, indicate that interactions between the c-kit receptor and its ligand importantly regulate normal mast cell development. However, certain other hematopoietic growth factors, in addition to regulating the proliferation of cells that express the appropriate receptors, can also significantly influence the functional activity of their target cells. For example, IL-3 represents a major growth factor for human basophils (13, 14) , but also both can function as an agonist that induces basophils to release histamine and other mediators, and can enhance the ability of basophils to release mediators in response to other secreta= gogues (15) (16) (17) (18) (19) (20) .
We have reported that rrSCF 164 can induce the release of serotonin (5-hydroxytryptamine) from BMCMC in vitro, but the magnitude of serotonin release is modest, and mediator release is observed only at concentrations of rrSCF 164 at least 10-fold higher than those that can induce proliferation of these cells (21) . However, different populations of mast cells can express multiple differences in phenotype, notably including variation in their sensitivity to the same agonists of mediator release (reviewed in reference 22). Moreover, certain agents that are relatively weak agonists of mast cell mediator release in vitro, such as PMA, represent potent stimuli of mast cell mediator release in vivo (23) . We therefore investigated the ability of rrSCF 164 to induce dermal mast cell activation when injected into the skin of mice in vivo, using approaches that permitted us to test dermal mast cells expressing either normal or functionally inactive forms of the c-kit receptor. Our results clearly indicate that rrSCF 164 represents a potent agonist of dermal mast cell activation, and show that this effect of rrSCF 164 requires that the mast cells express a functionally active c-kit receptor.
Materials and Methods
Recombinant SCE Recombinant rat SCF 164 (rrSCF 164) vcas purified from either Escherichia coli (E. coti-SCF) or Chinese hamster ovary cells (CHO-SCF) (5, 6) . In some experiments, we used E. coli-derived rrSCF 164 that had been modified by the covalent attachment of polyethylene glycol (6) . The various forms of rrSCF 164 were kept as stock solutions at 4~ in PBS and were diluted for intradermalinjection in Hanks' MEM (HMEM) containing piperazine-N,N'bis[2-ethane sulfonic acid] (HMEM/Pipes)just before use (24) . Similar dilutions of PBS alone in HMEM/Pipes were used for control injections. In most experiments, the left ears received injections of rrSCF 1~4 in 0.02-ml volumes (challenged ears), whereas the right ears received 0.02 ml of the vehicle (control ears). E. coli-derived rrSCF 164 was used for the most of our experiments. According to the iimulus amebocyte lysate chromogenic assay (LAL Assay; Whitaker Bioproducts Inc., Walkersville, MD), the endotoxin content of the highest concentration of this preparation used for our studies (51 #g/ml in HMEM/Pipes, to provide 30 #g/kg/dose), was 13.1 EU/ml ("~1.5 ng/ml), whereas the value for the HMEM/Hpes alone was 2.3 EU/ml (0.27 ng/ml). Based on these values and the volume of the reagents injected (20 #1), the amounts of endotoxin that were administered in these preparations were at least 30-to 200-fold less than that required to elicit significant inflammation when injected into the skin of mice (25 ]) were purchased from The Jackson Laboratory (Bar Harbor, ME). C57BL/6 mice were purchased from the Charles River Laboratories (Wilmington, MA).
The skin of adult W/W ~ (26) or Sl/SI a (27) mice contains <1.0% the number of dermal mast cells present in the skin of the congenie normal (+/+) mice. All mice were used at 2-7 mo of age unless stated otherwise.
Measurement of Tissue Swelling and Assessment of Mast Cell Activation. Ear swelling was determined by measurements of ear thickness with a micrometer before and at various intervals after the injection of rrSCF 164 or vehicle; swelling was expressed as the increment (A) of thickness (postinjection value -preinjection baseline value) in units of 10 -4 in (23, 24) .
In all experiments, tissue from the injection sites was obtained after the mice were killed by cervical dislocation and were processed for 1-/~m Epon-embedded, Giemsa-stained sections (28, 29) . Sections were coded and then were examined by observers who were unaware of the identity of individual sections. The number of mast ceils per square millimeter of dermis in each biopsy specimen was determined as previously described (23, 24) , and the mast cells were classified morphologically as exhibiting extensive degranulation (50% of the cytoplasmic granules exhibiting fusion, staining alterations, and/or extrusion from the cell), moderate degranulation (10-50% of the granules exhibiting altered or discharged), or no significant degranulation ("none"; <10% of the granules exhibiting alternatives (23, 24) .
Assessment of SCFqnduced ~2~I-Fibrin Deposition. In most experiments, we assessed altered vascular permeability using a very sentitire assay for detecting extravasation of lzSI-guinea pig fibrinogen (12sI-GPF) and deposition of crosslinked 12sI-fibrin (30, 31) . At 20-30 rain before challenge with SCF, the mice were injected intravenously with ~2-3 x 106 cpm of lzSI-GPF. The swelling responses in SCF-and control-injected ears were measured with a micrometer 1 and 2 h after challenge as described above. The mice then received a mixture of anticoagulants and antifibrinolytic agents intravenously to impede clotting or fibrinolysis during specimen preparation: each mouse received 0.2 ml of a mixture containing 80 U heparin, 20 #g D-phenyhlanyl-t-prolyl-L-arginine chloromethyl ketone, 2 #g e-aminocaproic acid, and 56 U trasylol, all in 0.15 M NaC1. Immediately thereafter, the mice were lightly anesthetized with ether, and a sample of retroorbital blood was obtained. These samples, which exhibited no clotting during an observation period of 3 h, were centrifuged at 10,000 g at room temperature to prepare platelet-poor plasma for radioactive counting. The mice were killed by cervical dislocation immediately after retroorbital bleeding, and both ears were amputated and trimmed. A small furl=thickness biopsy of each ear was fixed as described above for histologic studies. The rest of each ear was then promptly minced into fine fxagments in 2-ml 0.01 M phosphate buffer (pH 7.5) containing a mixture of proteolytic inhibitors: heparin (10 U/ml), D-phenylahnyl-t-arginlne chloromethyl ketone (5 mg/ml), EDTA (2 mg/ml), e-aminocaproic acid (0.1 M), trasylol (10 U/ml), 2 mM PMSF, 2 mM iodoacetate, and 2 mM N-ethylmaleimide. The minced ears were then extracted in the buffer by keeping the tubes for 18 h at 4~ Each tube was centrifuged (1,000 g for 20 rain at 20~
and supernatant was decanted. The pellet containing the tissue fragments was resuspended vigorously in 2 ml of the same buffer and was centrifuged again, as above. The supernatant was aspirated and pooled with the earlier extract for radioactive counting as the "aqueous extract:' The pelleted tissue fragments were suspended in 2 ml of freshly prepared 3-M urea, extracted for 2 h at 37~ centrifuged (1,000 g for 20 min at 20~ and the urea-soluble supernatant and the ureainsoluble pellet counted for radioactivity in a Tm Analytic 1193 gamma counter. *~SI-GPF--derived species present in mouse tissues consist of a mixture of fibrinogen, fibrin, and fibrinogen-fibrin degradation products (31) . The "urea-insoluble" residue consists
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Rat (23, 24, 31) . We reported that IL,3-dependent BMCMC of WBB6F~-+/+ origin maintained in suspension culture represent immature mast ceils that express certain phenotypic similarities to mucosal mast cells, but that upon injection into the skin (23, 24, 31, 32) of WBB6F1-W/W ~ mice, these mast cell populations gradually (over a 10-wk period) acquire multiple phenotypic characteristics of the mature connective tissue-type mast cells (CTMC) present in the dermis of normal mice. Moreover, injection of BMCMC into one ear of W/I,W mice repairs the mast cell deficiency in that ear alone. The mice remain mast cell deficient at other cutaneous sites and in other organs, and remain anemic as well (23, 24, 31, 32) . Briefy, bone marrow cells from WBB6Ft +/+ mice were grown in vitro for 3-5 wk in concamvalin A-stimulated mouse spleen cell-conditioned medium until mast ceils represented >95% of the total ceils as determined by neutral red staining. Mast cells (0.5 x 106) in 20 /zl of DMEM (Gibco l.aboratories, Grand Island, NY) were injected into the left ears and 20/~1 of medium alone into the right ears. The mice were used for experiments 10 wk after injection of mast cells. In each experiment, we confirmed histologically that local reconstitution of dermal mast ceil populations had occurred and determined that the W/W ~ mice locally reconstituted with mast cells remained anemic.
Induction of Cutaneous Mast Cells in W/W ~ and Congenic +/+ Mice by the Chronic Application of PMA.
We previously showed that the chronic epicutaneous application of PMA to the skin of genetically mast cell-deficient W/W ~ mice induces the development of mature dermal mast cells that morphologically and histochemically resemble the dermal CTMC of normal mice and that are fully competent to orchestrate IgE-dependent passive cutaneous anaphylaxis responses (33) . Moreover, these PMA-induced W/W v mast cell populations persist at the treated sites even after PMA treatment has been stopped to permit the inflammatory reactions at these sites to wane (34) . For these experiments, W/W ~ mice and congenic +/+ mice received 5 #g of PMA in 5 #1 of acetone to the inner surface of the left ear and acetone alone to the inner surface of the right (control) ear, three times a week for 6 wk. The mice received no treatment for an additional 16 d and then were used in an experiment. Some mice from both W/W ~ and congenic +/+ groups received E. coli--defived SCF (10 t.tg) into both ears, whereas other mice from both groups received a similar dilution of PBS in HMEM/PIPES into both ears. The latter groups represented controls for any possible effects of the chronic PMA treatment alone on cutaneous vascular permeability. Ear swelling measurements, assessment of P~I-fibrin deposition, and histology were performed as described above. To test the ability of W/W ~ mast cells to orchestrate passive cutaneous anaphylaxis responses, reactions were elicited as previously described (31) by injecting a monoclonal anti-DNP IgE (35) or vehicle alone into the ears and then challenging the mice "~24 h later by injecting 100/zg of DNP human serum albumin (DNP~.~HSA) (Sigma Chemical Co., St. Louis, MO) intravenously in 0.1 ml of sterile 0.9% NaC1 containing 1.0% Evans blue dye (Sigma Chemical Co.). The reactions were assessed 2 h after antigen challenge by visualization of the blue dye as well as by assessment of tissue swelling, 12sI-fibrin deposition, and histology, as noted above.
StatisticalAnalysis. The results of ear swelling assays, and differences in mast cell counts in different groups of mice, were analyzed for statistical significance (p < 0.05) by the unpaired Student's t test (two-tailed); comparison of values in the left (challenged) versus right (control) ears of the same mice was performed using the paired Student's t test (two-tailed). Ratios of radioactivity in left (challenged) versus fight (control) ears were analyzed by the MannWhitney U test (two-tailed). The extent of mast cell activation (marked degranulation, moderate degranulation, normal) was assessed using the X 2 test. Each experimental group contained four to five mice. All results are expressed as the mean _+ SEM.
Results

SCF Induces Cutaneous Inflammation and Mast Cell Activation In Viva
We first determined whether rrSCF 164 could induce mast cell activation and an acute inflammatory response when injected at doses similar to those that induce mast cell proliferation in vivo (2) . Fig. 1 shows that all three forms of rrSCF 164 tested, including CHO-derived (glycosylated) rrSCF1% E. coli-derived (nonglycosylated) rrSCF 164, and PEG-rrSCF 164, induced the rapid development of tissue swelling and nsI-fibrin deposition when injected into the skin of normal mice at 30/zg/kg/site.
We then evaluated the effect of injecting different doses of E. coli-derived rrSCF 164 into the skin of C57BL/6 mice. rrSCF 164 induced significant lzsI-fibrin deposition (Fig. 2 A) "~176176 l i ~ SCF-Injected .... 
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Wershil et al. and tissue swelling (Fig. 2 B) in doses as low as 0.1 #g/kg (~140 fmol) per site. When the results were expressed as the ratio of the crosslinked t2sI-fibrin-associated cpm in rrSCFt64-challenged as opposed to vehicle-injected mice (Fig.  2 A) , the amount of 12sI-fibrin at rrSCF t64 injected sites was ~21 times that at control sites at a dose of 10/zg/kg and "~5 times that at control sites at a dose of 0.1/zg/kg. Histological analysis demonstrated extensive mast cell activation at the sites that had been injected with all three forms of rrSCF t64, but not at control sites injected with vehicle (Table 1) . Moreover, the intradermal injection of various doses ofE. coli-SCF in the experiments reported in Fig. 2 induced a dose-dependent activation of dermal mast cells (Table 1) . Mast cell activation was extensive at the higher doses tested (e.g., 75 _+ 2% and 73 +_ 10% extensively degranulated mast cells at sites injected with E. coli-SCF at 30 and 1.0/zg/kg/site, respectively). However, even at doses at low as 0.1/~g/kgAite, activation of mast cells at rrSCF t~a injection sites was significantly greater than that at contralateral control sites injected with vehicle alone. Comparison of these findings to the results of our previous study of the effects of substance P on dermal mast cell activation (24) indicates that rrSCF 164 is at least 10 times more potent on a molar basis as a dermal mast cell activating agent than is substance P.
Cutaneous Inflammation Induced by SCF is Mast Cell-Dependent. To determine the extent to which the acute inflammation induced by intradermal rrSCF 164 is mast cell dependent, we injected rrSCF 164 into the skin of genetically mast cell-defirient mice and the congenic normal mice. We first tested W/kV v mice and their normal (+/+) littermates. Fig. 3 A shows that injection of E. coli-rrSCF t64 at 30/zg/ kgAite produced neither significant tissue swelling nor significant t2sI-fibrin deposition in the skin of W/W ~ mice, whereas the identically challenged normal littermates exhibited the expected inflammatory responses. In other experiments, W/W v mice gave no significant response to doses of rrSCF t64 as high as 100 Izg/kg/site (data not shown).
The results obtained with W/W ~ mice are consistent with the possibility that mast cells are required for the proinflammatory effects of rrSCF t64. However, these experiments are also consistent with a second possibility: rrSCFt+4-induced inflammation is mast cell independent but requires an intact c-kit receptor. To address this possibility, we injected rrSCF t64 into genetically mast cell-deficient SI/SI ~ mice. These animals express a normal c-kit receptor, but virtually lack cutaneous mast cells. As shown in Fig. 3 B, rrSCF 164 (30/~g/kgAite) produced no detectable inflammation when injected intradermally into the skin of SI/SI a mice. By contrast, the normal (+/+) littermates gave a strong response (Fig. 3 B) . The failure of even high doses of rrSCF 164 to induce any detectable augmented vascular permeability, tissue swelling, or t2sI-fibrin deposition in W/W v or SI/S! d mice indicates that it is the lack of mast cells in these mutants, not abnormalities in the c-kit receptor per se, that is responsible for the animals' unresponsiveness to the proinflammatory effects of rrSCF 164. This conclusion is supported further by the demonstration that reconstitution of W/W" mice with mast cells of congenic +/+ origin permits these mice to develop an inflammatory response to intradermal challenge with rrSCF t64 (see below). Fig. 4 shows that W/W ~ mice that contained adoptively transferred dermal mast cell populations of +/+ origin developed tissue swelling and extensive deposition of lzsI-fibrin at sites of rrSCF t~ injection. Note that rrSCF ~4 induced an inflammatory response only in the left ears of these W/W v mice, i.e., in those ears in which dermal mast cells had been selectively reconstituted by local injection of BMCMC of WBB6Ft-+/+ origin. The number of mast cells in these ears was 34 _+ 3/mm 2 of dermis, of which 34 + 4% or 34 _+ 4% exhibited extensive or moderate &granulation, respectively. By contrast, the mast cell-deficient right ears of these same mice (0 mast cells/mm z) developed little or no reaction in response to rrSCF 164 injection. We also injected rrSCF 1~ (10/zg/kg/site) into the ears of W/W ~ mice that had undergone repair of their mast cell deficiency as a result of intravenous injection of bone marrow cells of WBB6Ft-+/+ origin. The extent of mast cell degranulation, and the inflammatory responses, observed in these mice were similar in magnitude to those in identically challenged +/+ mice (data not shown). In contrast to W/W ~ mice containing adoptively transferred mast cell populations of +/+ origin, W/W ~ mice that contained PMA-induced dermal mast cells of W/W ~ origin developed no significant tissue swelling or lZSI-fibrin deposition at sites injected with 10/tg/kg of rrSCF ~64 (Fig.  5 A) . This finding reflected neither a general unresponsiveness of the W/W ~ dermal mast cells nor a suppression of mast cell reactivity at sites of PMA treatment. Thus, W/W ~ mast cells at sites of PMA treatment were able to orchestrate passive cutaneous anaphylaxis reactions which were similar in magnitude to those observed in the P/VIA-treated ears of the congenic +/+ mice (p > 0.05 by the Student's t test, two-tailed) (Fig. 5 C) . Moreover, in WBB6FI-+/+ mice, sites treated chronically with PMA developed amounts of rrSCFt64-induced (Fig. 5 B) , or IgE and antigen-induced (Fig. 5 C) tissue swelling and a2sI-fibrin deposition that actually exceeded those recorded at identically challenged contralateral sites that had been treated with acetone alone. This result indicates that chronic PMA treatment does not reduce, and actually appears to enhance, mast cell-dependent responses to challenge with either rrSCF 164 or IgE and antigen in 249 Wershil et al.
normal (+/+) mice. Furthermore, comparison of the results obtained at PMA-treated or acetone-treated sites that had been challenged with vehicle indicated that chronic treatment with PMA did not significantly augment baseline levels of vascular permeability at these sites either in W/W v mice (Fig.  5 A) or in +/+ mice (Fig. 5 B) . Fig. 5 , A and B report the results of one of two independent sets of experiments, both of which gave similar results. Histological analysis of the injection sites of the mice reported in Fig. 5 confirmed that mast cells had developed at sites of PMA treatment in W/W v mice, but not at contralateral control sites treated with acetone alone, and also showed that PMA treatment increased numbers of dermal mast cells in +/+ mice ( Table 2) . Dermal mast cells of +/+ origin in the PMA-or acetone-treated skin of +/+ animals exhibited extensive degranulation when examined 2 h after challenge with rrSCF le4 (Table 2) . By contrast, little or no mast cell activation was exhibited at sites of rrSCF 164 challenge in the PMA-treated skin of W/W ~ mice (Table 2) . Indeed, the extent of mast cell activation observed at sites of rrSCF t64 injection in the PMA-treated skin of W/W ~ mice was not significantly different than that at sites of vehicle injection (p ~> 0.05 by the X 2 test). However, extensive degranulation of W/W ~ dermal mast cells was observed at sites of passive cutaneous anaphylaxis (Table 2 ). This result confirmed our previous work (33) Discussion rrSCF t64 induced dermal mast cell activation and a mast cell-dependent acute inflammatory response when injected intradermaUy at doses as low as 140 fmolsAite. On a molar basis, rrSCF 164 thus is at least 10-fold more potent as an activator of mouse dermal mast ceils than is the classical CTMC agonist substance P (24). Our results indicate that the ability of rrSCF 164 to induce augmented cutaneous vascular permeability, local fibrin deposition, and tissue swelling were primarily, and perhaps entirely, mast cell dependent. Injection of rrSCF 164 into either W/W v or SI/SY mast cell-deficient mice was without significant effect, even when the cytokine was injected at a dose 1,000 times that which induced significant mast cell activation and acute inflammation in +/+ mice. By contrast, rrSCF 164 was able to induce an acute inflammatory response when injected into the skin of W/W ~ mice repaired of their cutaneous mast cell defidency by the adoptive transfer of bone marrow ceils or BMCMC derived from the congenic normal (+/+) mice.
These observations posed at least two questions. First, by what mechanism does intradermal injection of rrSCF 164 induce mast cell activation? The cytokine could either activate mast cells directly or indirectly, via effects on other cell populations or mediators. And direct effects on the mast cell elther could be mediated by an interaction between rrSCF 164 and the c-kit receptor or could reflect c-kit receptor-independent mechanisms. Our experiments with W/W v mice strongly suggest that the ability of rrSCF 164 to induce mast cell activation is a direct effect of the cytokine and requires a functionally active c-kit receptor. Thus, rrSCF x64 induced extensive activation of dermal mast cells, as well as the rapid development of fibrin deposition and tissue swelling, in W/W ~ mice whose skin contained adoptively transferred populations of mast cells derived from the congenic +/+ mice. by contrast, injection of rrSCF 164 into the skin of W/W ~ mice that contained mast cells of W/W" origin induced neither mast cell activation nor an inflammatory response. Both our previous studies (33, 34) expression by these ceils of c-hit receptors with markedly impaired tyrosine kinase activity (36) . In contrast to its potency as an activator of dermal mast cells in vivo, rrSCF 164 is a relatively weak agonist of mast cell activation in vitro (21) . Certain populations of in vitro-derived mast cells exhibited modest activation in response to challenge with rrSCF 164, but these effects were observed only at concentrations of rrSCF 164 of 50-500 ng/ml, levels 10-to 100-fold higher than those necessary to induce proliferation of these cells (21) . Moreover, rrSCF ;~4 did not induce significant [3H]SHT release from freshly purified mouse or rat peritoneal mast cells, even when tested at concentrations of up to 5.0 #g/ml (21) . Although the results of in vitro and in vivo experiments should be compared cautiously, 5.0 /~g/ml represents an *30-fold higher concentration of rrSCF 164 than the lowest concentration necessary to induce significant dermal mast cell degranulation and inflammation when injected intradermaUy in vivo. There are at least two possible explanations for the apparent differences in the responsiveness of mast ceils to challenge with rrSCF ;~4 in vitro or in vivo. First, optimal responsiveness to ITSCF 164 may require a cofactor that is present in the skin in vivo but not in the conditions tested in vitro. Second, responsiveness to rrSCF ;64 as a stimulus of mast cell mediator release may vary according to mast ceil phenotype. Although dermal mast ceils and peritoneal mast ceils are both regarded as examples of CTMC in routine rodents (reviewed in reference 22), these populations differ in size and morphometric characteristics of cytoplasmic granules (37) . They may also vary in their responsiveness to rrSCF 164, whether because of differences in the amounts of c-kit ligand expressed endogenously in the skin as opposed to the peritoneal cavity or because of other factors.
The second major question prompted by our observations concerns the biological relevance of the findings. We have reported that rrSCF ;~4 can induce c-k/t-dependent mast ceil proliferation in vitro (3) and in vivo (2) , and that rrSCF ;~ also can promote maturation of immature mast ceils, as judged 251 Wershil et al. These data are from the same experiments depicted in Fig. 5 . NS, not significant (p > 0.05) when compared to values for contralateral by several criteria including histamine content and pattern of proteoglycan synthesis in vitro (3) and histochemistry and pattern of protease synthesis in vivo (2) . Taken together with the profound mast cell deficiency expressed by both W/W V and SI/SI d mice (1, 12, 26, 27) , these findings leave little doubt that interactions between the c-kit receptor and its ligand are essential for normal mast cell development.
But it is more difficult to form a firm conclusion about the physiological importance of SCF as a stimulus of mast cell mediator release. Using different approaches, two groups recently showed that activation of the c-kit receptor kinase by ligand binding resulted in a pattern of intracellular signal transduction that included binding and complex formation between the c-kit receptor and phosphatidylinositol Y-kinase (38, 39) . However, these reports did not determine whether such c-kit receptor-dependent signal transduction resulted in mast cell mediator release. The data presented here indicate that rrSCF 164 can induce c-kit receptor-dependent mast cell activation and mediator release. In addition to demonstrating that mast cell activation via the c-kit receptor results in the development of a mast cell-dependent inflammatory response, our fndings represent, to our knowledge, the first evidence that administration of the c-kit ligand in vivo can stimulate the functional activation of any cell type that expresses the c-kit receptor.
However, normal tissues do not ordinarily exhibit significant mast cell degranulation, or express inflammatory responses, without some sort of provocation. If interactions between acetone-treated ears by the X 2 test. the c-kit receptor and its ligand importantly contribute to the maintenance of mast cell populations in normal tissues, as seems likely, then such interactions ordinarily must not result in sufficient mast cell activation to induce a perceptible inflammatory response. Several factors may account for the lack of detectable inflammation due to c-kit receptor-dependent mast cell activation in normal tissues. C-kit ligands exist in cell membrane-associated forms (9, 40, 41) and in soluble forms, such as that represented by rrSCF 164, which consist of the first 164 or 165 amino acids of the extraceUular domain (4-6, 9, 10, 41). Although both forms of the ligand are biologically active with respect to effects on proliferation (9, 41) , it is possible that soluble and membrane-associated forms of SCF may differ in their ability to induce mast cell degranulation. Moreover, no information is available concerning the levels of any forms of the c-kit ligand that are present in normal tissues. Nevertheless, the lack of significant mast cell degranulation in normal tissues would indicate that physiologic interactions between c-kit receptors expressed by mast cells and endogenous forms of the c-kit ligand do not generally result in extensive mast cell degranulation.
On the other hand, the possibility cannot be ruled out that low levels of mast cell mediator release induced by c-kit receptor-dependent mast cell activation may have a role in both the development and function of this cell type. Activation of mouse mast cells generated in vitro, via the Fc~KI or other mechanisms, induces the cells to develop increased levels of mKNA for several cytokines and/or to secrete the
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Rat c-kit Ligand Induces Mouse Mast Cell Activation products (42) (43) (44) (45) . Some of these cytokines, such as II. 1-3, and 12 ). Taken together with the findings presented here, these observations raise the possibility that one of the mechanisms by which SCF influences mast cell development is to induce mast cells to produce other cytokines with autocrine effects on mast cell proliferation and/or maturation.
In addition, there has been a long history of speculation that one "physiological" role of the mast cell is to release constitutively very low levels of the same mediators which, when released rapidly in larger quantities, result in the development of an inflammatory response (reviewed in reference 49). Although our data by no means prove that physiological interactions between the c-k/t receptor and its endogenous ligands actually result in low levels of mast cell mediator release in normal tissues, they nevertheless can be considered compatible with this hypothesis. Furthermore, our findings suggest that conditions that result in high local concentrations of soluble c-kit ligand, whether of endogenous or exogenous origin, may be associated with significant mast call activation in routine rodents. It will be important to determine whether the same is true for human mast cells, since this information will dearly influence the development of plans for any clinical applications of this cytokine.
